24 January 2024
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.
Oxford PharmaGenesis Inc., the independent, global HealthScience communications consultancy, is proud to announce that Kevin Ryder has joined their expanding US team as Vice President, Medical Services.
I was diagnosed with a 60 mm invasive lobular tumour in my left breast (estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 [HER2] negative) without lymph node involvement in June 2015. Fortunately, I found the lump myself (in between mammograms) and was able to get it detected quickly.
The contemporary era of healthcare has seen changes in the role of the patient. It used to be that patients were perceived as passive receivers of healthcare, but this has altered; the pharmaceutical industry and healthcare professionals are increasingly giving patients a voice and a role in decisions about their healthcare.
Now over 250 strong, the award-winning, independent HealthScience communications consultancy Oxford PharmaGenesis is pleased to announce the appointment of Corin Wing as Principal Medical Writer.
We didn’t just sit on our haunches when we celebrated our 20th anniversary in January 2018. We’ve been busier than ever this year at Oxford PharmaGenesis!
Oxford PharmaGenesis is pleased to announce an update to our publication policy, which provides clear ethical guidance on our involvement in publications.
